OBJECTIVES: Clinical staging is widespread in medicine - it informs prognosis, clinical course, and treatment, and assists individualized care. Staging places an individual on a probabilistic continuum of increasing potential disease severity, ranging from clinically at-risk or latency stage through first threshold episode of illness or recurrence, and, finally, to late or end-stage disease. The aim of the present paper was to examine and update the evidence regarding staging in bipolar disorder, and how this might inform targeted and individualized intervention approaches. METHODS: We provide a narrative review of the relevant information. RESULTS: In bipolar disorder, the validity of staging is informed by a range of findings that accompany illness progression, including neuroimaging data suggesting incremental volume loss, cognitive changes, and a declining likelihood of response to pharmacological and psychosocial treatments. Staging informs the adoption of a number of approaches, including the active promotion of both indicated prevention for at-risk individuals and early intervention strategies for newly diagnosed individuals, and the tailored implementation of treatments according to the stage of illness. CONCLUSIONS: The nature of bipolar disorder implies the presence of an active process of neuroprogression that is considered to be at least partly mediated by inflammation, oxidative stress, apoptosis, and changes in neurogenesis. It further supports the concept of neuroprotection, in that a diversity of agents have putative effects against these molecular targets. Clinically, staging suggests that the at-risk state or first episode is a period that requires particularly active and broad-based treatment, consistent with the hope that the temporal trajectory of the illness can be altered. Prompt treatment may be potentially neuroprotective and attenuate the neurostructural and neurocognitive changes that emerge with chronicity. Staging highlights the need for interventions at a service delivery level and implementing treatments at the earliest stage of illness possible.
OBJECTIVES: Clinical staging is widespread in medicine - it informs prognosis, clinical course, and treatment, and assists individualized care. Staging places an individual on a probabilistic continuum of increasing potential disease severity, ranging from clinically at-risk or latency stage through first threshold episode of illness or recurrence, and, finally, to late or end-stage disease. The aim of the present paper was to examine and update the evidence regarding staging in bipolar disorder, and how this might inform targeted and individualized intervention approaches. METHODS: We provide a narrative review of the relevant information. RESULTS: In bipolar disorder, the validity of staging is informed by a range of findings that accompany illness progression, including neuroimaging data suggesting incremental volume loss, cognitive changes, and a declining likelihood of response to pharmacological and psychosocial treatments. Staging informs the adoption of a number of approaches, including the active promotion of both indicated prevention for at-risk individuals and early intervention strategies for newly diagnosed individuals, and the tailored implementation of treatments according to the stage of illness. CONCLUSIONS: The nature of bipolar disorder implies the presence of an active process of neuroprogression that is considered to be at least partly mediated by inflammation, oxidative stress, apoptosis, and changes in neurogenesis. It further supports the concept of neuroprotection, in that a diversity of agents have putative effects against these molecular targets. Clinically, staging suggests that the at-risk state or first episode is a period that requires particularly active and broad-based treatment, consistent with the hope that the temporal trajectory of the illness can be altered. Prompt treatment may be potentially neuroprotective and attenuate the neurostructural and neurocognitive changes that emerge with chronicity. Staging highlights the need for interventions at a service delivery level and implementing treatments at the earliest stage of illness possible.
Authors: Craig A Macneil; Karen Hallam; Philippe Conus; Lisa Henry; Linda Kader; Michael Berk Journal: Expert Rev Neurother Date: 2012-01 Impact factor: 4.618
Authors: Michael Berk; Philippe Conus; Flávio Kapczinski; Ana C Andreazza; Murat Yücel; Stephen J Wood; Christos Pantelis; Gin S Malhi; Seetal Dodd; Andreas Bechdolf; G Paul Amminger; Ian B Hickie; Patrick D McGorry Journal: Med J Aust Date: 2010-08-16 Impact factor: 7.738
Authors: María Reinares; Francesc Colom; Adriane R Rosa; C Mar Bonnín; Carolina Franco; Brisa Solé; Flavio Kapczinski; Eduard Vieta Journal: J Affect Disord Date: 2009-10-23 Impact factor: 4.839
Authors: Rafael T de Sousa; Emilio L Streck; Orestes V Forlenza; Andre R Brunoni; Marcus V Zanetti; Gabriela K Ferreira; Breno S Diniz; Luis V Portela; André F Carvalho; Carlos A Zarate; Wagner F Gattaz; Rodrigo Machado-Vieira Journal: Neurosci Lett Date: 2015-08-20 Impact factor: 3.046
Authors: Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira Journal: J Psychiatr Res Date: 2013-12-06 Impact factor: 4.791
Authors: Giselli Scaini; Tatiana Barichello; Gabriel R Fries; Elizabeth A Kennon; Taylor Andrews; Bobby R Nix; Giovana Zunta-Soares; Samira S Valvassori; Jair C Soares; João Quevedo Journal: Neuropsychopharmacology Date: 2018-12-11 Impact factor: 7.853
Authors: A Peters; L G Sylvia; P V da Silva Magalhães; D J Miklowitz; E Frank; M W Otto; N S Hansen; D D Dougherty; M Berk; A A Nierenberg; T Deckersbach Journal: Psychol Med Date: 2014-04-10 Impact factor: 7.723
Authors: Martha Sajatovic; Sergio A Strejilevich; Ariel G Gildengers; Annemiek Dols; Rayan K Al Jurdi; Brent P Forester; Lars Vedel Kessing; John Beyer; Facundo Manes; Soham Rej; Adriane R Rosa; Sigfried Ntm Schouws; Shang-Ying Tsai; Robert C Young; Kenneth I Shulman Journal: Bipolar Disord Date: 2015-09-19 Impact factor: 6.744
Authors: Ann K Shinn; Kirsten W Bolton; Rakesh Karmacharya; Kathryn E Lewandowski; Cagri Yuksel; Justin T Baker; Virginie-Anne Chouinard; Samira M Pingali; Hilary Bye; Katherine Cederbaum; Dost Öngür Journal: Early Interv Psychiatry Date: 2015-11-29 Impact factor: 2.732
Authors: Jessica Dagani; Giulia Signorini; Olav Nielssen; Moira Bani; Adriana Pastore; Giovanni de Girolamo; Matthew Large Journal: Can J Psychiatry Date: 2016-07-11 Impact factor: 4.356
Authors: Rafael T de Sousa; Emilio L Streck; Marcus V Zanetti; Gabriela K Ferreira; Breno S Diniz; Andre R Brunoni; Geraldo F Busatto; Wagner F Gattaz; Rodrigo Machado-Vieira Journal: Psychopharmacology (Berl) Date: 2014-06-26 Impact factor: 4.530